Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:4495
Structure:
Synonyms:
4'-Nitro-2'-phenoxymethanesulfonanilide
4'-Nitro-2'-phenoxymethansulfonanilid
4-Nitro-2-phenoxy-methanesulfonanilide
4-NITRO-2-PHENOXYMETHANESULFONANILIDE
51803-78-2
AB00052332
AC-4524
AC1L1IAM
Alcala Brand of Nimesulide
Aldoron
Alter Brand of Nimesulide
Ambap693
Antifloxil
Aulin
BCBcMAP01_000034
Bio2_000382
Bio2_000862
BPBio1_000163
BRD-K76775527-001-06-2
BRN 2421175
BSPBio_000147
BSPBio_001103
BSPBio_003112
C012655
C13H12N2O5S
CAS-51803-78-2
CCG-39319
CCRIS 8225
CHEBI:44445
CHEMBL56367
D01049
DB04743
DivK1c_000693
EINECS 257-431-4
Ergha Brand of Nimesulide
Eskaflam
EU-0100855
Flogovital
Guaxan
Helsinn Brand of Nimesulide
HMS1362G05
HMS1568H09
HMS1792G05
HMS1922K17
HMS1990G05
HMS2089B14
HMS2095H09
HMS2234K19
HMS3262L11
HMS502C15
IDI1_000693
IDI1_002137
KBio1_000693
KBio2_000443
KBio2_002057
KBio2_003011
KBio2_004625
KBio2_005579
KBio2_007193
KBio3_000825
KBio3_000826
KBio3_002612
KBioGR_000443
KBioGR_000695
KBioSS_000443
KBioSS_002057
Lakeside Brand of Nimesulide
lizepat
Lopac-N-1016
Lopac0_000855
LS-90290
Maver Brand of Nimesulide
Mesulid
Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-
Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)- (9CI)
Methanesulfonanilide, 4'-nitro-2'-phenoxy-
MLS000069680
MLS001148268
MolPort-003-849-391
N 1016
N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide
N-[4-nitro-2-(phenoxy)phenyl]methanesulfonamide
N-[4-Nitro-2-phenoxyphenyl]-methanesulfonamide
N1016_SIGMA
NCGC00015725-01
NCGC00015725-02
NCGC00015725-03
NCGC00015725-04
NCGC00015725-05
NCGC00015725-06
NCGC00015725-07
NCGC00015725-08
NCGC00015725-09
NCGC00015725-10
NCGC00015725-11
NCGC00015725-12
NCGC00015725-13
NCGC00021842-03
NCGC00021842-04
NCGC00021842-05
NCGC00021842-06
NCGC00021842-07
NCGC00021842-08
nchembio.147-comp1
Nexen
NIM
NIM-03
Nimed
Nimedex
Nimesil
Nimesulida
Nimesulida [INN-Spanish]
NIMESULIDE
Nimesulide (JAN/INN)
Nimesulide [BAN:INN]
Nimesulidum
Nimesulidum [INN-Latin]
NINDS_000693
Nise Gel
Nisulid
Orthobid
Prestwick0_000194
Prestwick1_000194
Prestwick2_000194
Prestwick3_000194
Prestwick_618
R 805
R-805
Redaflam
SBB066407
SmithKline Beecham Brand of Nimesulide
SMR000058484
SPBio_001382
SPBio_002068
SPECTRUM1503231
Spectrum2_001541
Spectrum3_001576
Spectrum4_000178
Spectrum5_000964
Spectrum_001577
STL018679
Sulidene
Th?rabel Brand of Nimesulide
ATC-Codes:

Target

show target details
Uniprot ID:POKL_HUMAN
Synonyms:
Putative HERV-K_Xq28 provirus ancestral Pol protein
EC-Numbers:2.7.7.49
Organism:Homo sapiens
Human
PDB IDs:-

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----

References:

15309882
Cyclooxygenase-2 inhibitor nimesulide suppresses telomerase activity by blocking Akt/PKB activation in gastric cancer cell line.. Yu Baoping; Hu Guoyong; Yu Jieping; Ran Zongxue; Luo Hesheng (2004) Digestive diseases and sciences display abstract
Nonsteroidal antiinflammatory drugs (NSAIDs) have been reported to have antiproliferative effects in neoplastic cells of different origin during the past few decades. We aimed to study the effects of the selective COX-2 inhibitor, nimesulide, on cell viability and telomerase and Akt/PKB activity in the human gastric cancer cell line MKN-45 and to explore the molecular mechanism for the antitumor activity of the selective COX-2 inhibitor. We tested the influence of nimesulide on the gastric cancer cell line MKN-45 in vitro. Trypan blue exclusion was used to determine the cell viability after incubation for 0, 12, 24, and 48 hr in different concentrations of nimesulide 0, 25, 50, 100, 200 microM). After treatment or no treatment with 100 microM nimesulide for 0, 12, 24, or 48 hr in the presence or absence of 300 nM okadaic acid for 2 hr, telomerase and Akt/PKB activity was measured using TRAP PCR-ELISA and nonradioactive IP kinase assays, respectively. In the gastric cancer cell line MKN-45 nimesulide caused a time- and dose-dependent reduction in cell numbers and significantly inhibited telomerase and Akt/PKB activity; the inhibition of telomerase activity was partly associated with the attenuation of Akt/PKB activity. These results demonstrate that the selective COX-2 inhibitor suppresses the telomerase activity of gastric cancer cells, in part by blocking the activation of protein kinase B, which provides a new signaling mechanism responsible for the anticancer effects of the selective COX-2 inhibitor.